Hong Kong Pharma Digital Technology (NASDAQ:HKPD) Shares to Reverse Split on Monday, October 26th

Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD)’s stock is scheduled to reverse split before the market opens on Monday, October 26th. The 1-20 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, October 25th.

Hong Kong Pharma Digital Technology Stock Performance

Shares of Hong Kong Pharma Digital Technology stock opened at $0.10 on Thursday. The company has a current ratio of 3.86, a quick ratio of 3.75 and a debt-to-equity ratio of 0.01. Hong Kong Pharma Digital Technology has a 12-month low of $0.08 and a 12-month high of $1.72. The business’s 50 day moving average is $0.19 and its 200-day moving average is $0.39.

Hong Kong Pharma Digital Technology (NASDAQ:HKPD) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.04) EPS for the quarter. The firm had revenue of $3.15 million during the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered shares of Hong Kong Pharma Digital Technology from a “sell (d)” rating to a “sell (e+)” rating in a research report on Thursday, August 13th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Hong Kong Pharma Digital Technology Company Profile

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.